|
May 13
|
3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%
|
|
May 13
|
Pipeline Moves: Phase III completion for Corcept’s relaorilant
|
|
May 3
|
Corcept Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 2
|
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
|
|
May 2
|
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
|
|
May 2
|
Q1 2024 Corcept Therapeutics Inc Earnings Call
|
|
May 2
|
Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
|
|
May 1
|
Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024
|
|
May 1
|
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
|
|
Apr 29
|
Corcept Completes Enrollment in Phase 4 CATALYST Trial
|
|
Apr 24
|
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
|
|
Apr 23
|
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
|
|
Apr 22
|
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
|
|
Apr 17
|
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
|
|
Apr 16
|
Corcept (CORT) Completes Enrollment in Phase II ALS Study
|
|
Apr 15
|
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
|
Apr 9
|
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
|
|
Apr 8
|
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
|
|
Apr 1
|
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
|
|
Mar 29
|
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
|